Skip to main content

Insulin delivery devices and technology

medwireNews

10-18-2023 | Type 1 diabetes | News

Automated insulin delivery benefits type 1 diabetes individuals at high hypoglycemia risk

Automated insulin delivery reduces hypoglycemia in people with type 1 diabetes at increased risk, improving their time spent in target glucose range.

06-02-2023 | Type 1 diabetes | News

Pregnancy-specific closed-loop system proves feasible for home use

Results of a pilot study show that a hybrid closed-loop insulin delivery system customized for pregnancy used by women with type 1 diabetes at home significantly improved their glucose outcomes.

Senior man with glucometer checking blood sugar

11-29-2022 | Older adults | News

Call to rethink CGM advice for older adults

Analysis of participants in the ORACL trial leads researchers to suggest that nonfrail older adults with type 1 diabetes are better off following time in range guidance aimed at younger people.

09-23-2022 | EASD 2022 | Conference coverage | News

Bolus timing requires more attention in people using advanced technologies for type 1 diabetes

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

Girl with CGM

09-21-2022 | EASD 2022 | Conference coverage | News

Skin reactions rarely lead to diabetes device discontinuation

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

09-20-2022 | EASD 2022 | Conference coverage | News

Insulin pump delivery may reduce fatty liver risk in type 1 diabetes

Using an insulin pump rather than multiple daily injections may help protect people with type 1 diabetes from developing fatty liver disease, report researchers.

06-08-2022 | ADA 2022 | Conference coverage | News

OpenAPS closed-loop algorithm improves glucose control in formal trial

Closed-loop insulin delivery with the open-source OpenAPS algorithm results in significantly better glucose control than sensor-augmented pump delivery in children and adults in the randomized CREATE trial.

03-11-2022 | Insulin pumps | News

Insulin pump infusion set failures most common in youngest users

Insulin pump infusion set failures that result in prolonged hyperglycemia occur an average of four times per year per user and are more common in children and adolescents than adults, US study findings indicate.

08-20-2021 | Ultra-rapid lispro | News

FDA approves ultra-rapid lispro for use in pumps

Click through to read more on this announcement

05-13-2021 | Insulin pumps | News

Similar glycemic control with insulin pumps vs MDI in children with type 1 diabetes

Use of an insulin pump is not associated with better glycemic control than multiple daily injections among children and adolescents with type 1 diabetes, indicate real-world study results.

03-31-2021 | Older adults | News

Glargine-300 might be preferable for older people with type 2 diabetes

Analysis of older participants in the BRIGHT trial suggests that this subgroup may do slightly better with insulin glargine-300 than with degludec.

Glucose chart

03-22-2021 | Hypoglycemia | News

Hypoglycemia treatment advice needs modifying for low-glucose suspend systems

The amount of carbohydrate needed to treat mild or moderate hypoglycemia in people with type 1 diabetes using a predictive low-glucose suspend system may be considerably lower than what is currently recommended, report researchers.

12-11-2020 | Ethnic groups | News

Racial minorities have reduced likelihood of receiving diabetes technologies

US researchers have identified racial disparities in the receipt of diabetes technologies among young adults with type 1 diabetes.

Child with insulin pump

12-02-2020 | Insulin pumps | News

Real-world data support early insulin pump initiation in children

Starting children on an insulin pump within 6 months of type 1 diabetes diagnosis is associated with improved outcomes relative to delaying for 2 or 3 years, shows an analysis of data from the DPV registry.

11-09-2020 | Continuous glucose monitoring | News

Children persist best with CGM if started concurrently with insulin pump

Children with type 1 diabetes make more consistent use of continuous glucose monitoring if they are given the device when they initiate insulin pump therapy, rather than several months later, show the CGM TIME Trial results.

Artificial pancreas concept

11-06-2020 | Artificial pancreas systems | News

Closed-loop system shows promise for people with unstable type 1 diabetes

A closed-loop insulin delivery system may offer significantly better glycemic control than an open-loop system with predictive low glucose suspend in islet transplant candidates with highly unstable type 1 diabetes, research shows.

05-18-2020 | Type 1 diabetes | News

Characteristics of adult- versus childhood-onset type 1 diabetes documented

Age at type 1 diabetes diagnosis does not appear to affect glycemic control and comorbidity once disease is established, but important differences occur between age groups at the time of diagnosis, US study data show.

01-08-2020 | Insulin pumps | News

Lower HbA1c achieved with CSII vs MDI for U-500R in type 2 diabetes

Continuous subcutaneous insulin infusion of recombinant human regular U-500 insulin leads to greater glycated hemoglobin reductions at a much lower dose than multiple daily injections in people with type 2 diabetes, US research shows.

Insulin pump

01-07-2020 | Insulin pumps | Highlight | News

Insulin pumps may help stabilize glucose levels over the long term

Continuous subcutaneous insulin infusion users have more stable glycated hemoglobin levels over the long term than multiple daily injection users with type 1 diabetes, a real-world study suggests.

11-22-2019 | Liraglutide (obesity) | News

Add-on liraglutide benefits overweight insulin pump users with poor glycemic control

Adding liraglutide to continuous subcutaneous insulin infusion significantly reduces glycated hemoglobin without increasing hypoglycemia in overweight and obese people with type 1 diabetes and suboptimal glycemic control, Danish research shows.